Jade Biosciences (NasdaqCM:JBIO) Conference Transcript

Summary of Jade Biosciences Conference Call Company Overview - Company: Jade Biosciences (NasdaqCM: JBIO) - Focus: Development of best-in-class therapeutics for autoimmune diseases, particularly through high-affinity monoclonal antibodies sourced from Paragon Therapeutics [2][36] Key Points on IGAN and Therapeutic Landscape - Lead Program: Anti-APRIL antibody (Jade 101) targeting Immunoglobulin A Nephropathy (IGAN) with a market potential exceeding $10 billion in the U.S. [3][37] - Clinical Stage: Recently transitioned to a clinical stage company with the first cohort dosed, aiming for first-in-human readout in the first half of next year [4][38] - Current Treatment Landscape: Most patients currently receive ACE inhibitors or ARBs, with additional therapies like SGLT2s and immunosuppressants added if proteinuria targets are not met [6][40] - Emerging Therapies: New KDIGO guidelines propose that all patients should receive agents proven to reduce pathogenic IgA, positioning selective anti-APRIL therapies as frontline treatments [7][41][42] Jade 101 Development Insights - Dosing Schedule: Targeting a subcutaneous injection every eight weeks, which is more convenient than existing therapies [3][37] - Potency and Affinity: Jade 101 has a femtomolar affinity to APRIL, significantly higher than competitors, allowing for effective suppression at lower doses [13][47] - Mechanism of Action: Designed to prevent large immune complex formation, reducing immunogenicity risks and enhancing pharmacokinetics [16][49] Clinical Data and Efficacy - Phase Two Data: Previous studies showed that full APRIL suppression led to significant proteinuria reduction and stabilization of eGFR, with a safety profile comparable to placebo [20][54] - Long-term Goals: Aiming to achieve proteinuria levels below 0.3 grams per day to minimize long-term kidney failure risks [22][55] Future Development Plans - Phase One Trial: Scheduled for the first half of next year in New Zealand, with plans for a targeted open-label phase two study to quickly gather proof of concept data [56][58] - Regulatory Interactions: Engaging with regulators to ensure efficient development pathways, particularly in light of new therapies entering the market [59][61] - Exploration of Other Indications: Potential expansion into other IGM-driven diseases, pending positive phase one results [63][64] Financial Position - Funding: Closed the last quarter with $221 million, sufficient to fund operations through 2027, including the advancement of Jade 101 and other programs [32][66] Conclusion - Jade Biosciences is positioned to capitalize on the growing market for IGAN therapies with its innovative anti-APRIL antibody, Jade 101, and is actively pursuing clinical development while maintaining a strong financial foundation.